No Data
No Data
Regeneron Pharma Is Maintained at Neutral by Cantor Fitzgerald
Regeneron Pharma Is Maintained at Neutral by Cantor
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
Regeneron Pharmaceuticals (REGN) has an average outperform rating and price target range of $720 to $1,300, according to analysts polled by Capital IQ.Price: 1,069.52, Change: +5.92, Percent Change: +
Express News | Regeneron Pharmaceuticals Inc : Jefferies Raises Target Price to $1,235 From $1,135
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Regeneron Pharmaceuticals's (NYSE:REGN) short percent of float has risen 10.17% since its last report. The company recently reported that it has 2.04 million shares sold short, which is 1.95% of all
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Regeneron Pharmaceuticals (REGN) has an average outperform rating and a price target range of $720 to $1,250, according to analysts polled by Capital IQ.
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,166
Piper Sandler analyst Christopher Raymond maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,000 to $1,166.According to TipRanks data, the analyst
RDK79 : I recognized one word in that lead sentence:)))
But it sounds like good news!!!